Quantum Genomics is launching a public equity offering on Alternext Paris, above all to fund the phase IIa clinical trials of its antihypertensive drug candidate QGC001

Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the launch of a public equity offering of approximately 9.1 M€ on the Alternext market, part of Euronext Paris.

•      > Capital increase of approximately 9.1 M€,

•      > Purchase agreement with shareholders for a maximum of €5 M

•      > Indicative price range: €5.40 – €6.30

•      > Subscription period from 27 January to 12 February 2015

 

[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/01/QGC_PR_Capital-increase_20150127_UK.pdf” target=”_blank” title=”Download press release” size=”small” color=”red”]